MARSHALL WACE, LLP

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in NTLA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,761,787

+$650,136 QoQ

Shares Held

137,425

+44.1% QoQ

Ownership

0.098%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

10 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. NTLA ranks #165 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,761,787	137,425	+44.1%	Shares	Other	2026-05-15
2024-12-31	$1,111,651	95,339	-71.6%	Shares	Other	2025-02-13
2024-03-31	$9,227,074	335,408	-62.3%	Shares	Other	2024-05-15
2023-12-31	$27,151,284	890,498	+128.9%	Shares	Other	2024-02-14
2022-12-31	$13,574,791	389,074	+5157.8%	Shares	Other	2023-02-14
2022-09-30	$414,104	7,400	-26.9%	Shares	Other	2022-11-14
2022-06-30	$524,017	10,124	-90.5%	Shares	Other	2022-08-15
2022-03-31	$7,725,983	106,316	+613.1%	Shares	Other	2022-05-16
2021-03-31	$1,196,521	14,909	+10.7%	Shares	Sole	2021-05-17
2020-12-31	$732,550	13,466	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.